Author | Anthony Mato, MD | OncLive

Author | Anthony Mato, MD

Articles

Dr. Mato on Managing Side Effects With Ibrutinib/Idelalisib in CLL

August 24, 2016

Video

Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).

x